

Early Biotech Playbook: Fireside Chat with Medicilon
Join us for a fireside chat with Dr. Chunlin Chen, the CEO of Medicilon, moderated by Md Kabir, CEO of Valenyx Therapeutics, followed by a networking happy hour hosted by Medicilon, Valenyx Therapeutics, and Nucleate New York at South Park Commons NYC.
Whether you are a scientist curious about the business side of biotech, an aspiring investor, or a founder thinking about fundraising, this conversation will give you some insights on the global preclinical and early-stage biotech landscape.
📅 Friday, December 4th
⏰ 4:00–6:00 PM
Agenda
3:30 PM: Doors open
3:30-4:00 PM: Networking
4:00-5:00 PM: Fireside chat
5:00-6:00 PM: Networking + Happy Hour
A huge thank you to our event sponsor, Medicilon, South Park Commons, and Valenyx Therapeutics, for helping make this event possible.
We can’t wait to see you there!
Dr. Chunlin Chen is the Founder, Chairman & CEO of Medicilon USA Corp. and Shanghai Medicilon Inc. ($1.58B market cap), a global preclinical CRO providing chemistry, biology, and ADMET services to pharmaceutical and biotechnology companies. Dr. Chen earned his Master of Science degree in Pharmacy from China Pharmaceutical University in 1986 and his Ph.D. in Pharmacology and Toxicology from Oklahoma State University, USA, in 1994. Following his doctoral studies, Dr. Chen conducted extensive research in pharmacology, toxicology, and biochemistry. Prior to founding Medicilon, he gained substantial professional experience in the United States, serving as a Staff Investigator in the Department of Pharmacokinetics and Metabolism at Vertex Pharmaceuticals and as Director of the Pharmaceutical Department at Parker Hughes Cancer Center. In early 2004, Dr. Chen returned to China and founded Shanghai Medicilon Inc., which has provided drug discovery and development services to 2,000+ biotech and pharmaceutical companies, universities, and research institutions, supporting 700+ IND approvals.
Medicilon is a one-stop preclinical CRO with 22+ years of experience, providing integrated drug discovery, CMC development, and preclinical research services spanning chemistry, biology, ADME/DMPK, pharmacology, safety assessment, and IND-enabling studies.
Valenyx Therapeutics is pioneering nanobody-conjugates that can reach where antibodies cannot. Valenyx's AI-engine leverage evolution as a generative model and is advancing first-in-class nanobody-drug-conjugate (NDC) for the treatment of pancreatic cancer.
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.org for more information, and visit https://nucleate.org/privacy-policy/ to read our privacy policy.
We want to thank our HQ supporters for championing our open-access mission and empowering the next generation of biotech entrepreneurs!: